Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
Authors
Keywords
-
Journal
Dermatology and Therapy
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-05-11
DOI
10.1007/s13555-022-00734-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis
- (2021) J.I. Silverberg et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies
- (2021) Timo Buhl et al. Dermatology and Therapy
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis
- (2021) Andrew Blauvelt et al. JAMA Dermatology
- Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis
- (2021) Jonathan I. Silverberg et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis
- (2021) Jonathan I. Silverberg et al. Health and Quality of Life Outcomes
- Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
- (2020) E.L. Simpson et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis
- (2020) Kristian Reich et al. JAMA Dermatology
- Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis
- (2019) Vibeke Strand et al. Journal of Comparative Effectiveness Research
- Janus kinases to jakinibs: from basic insights to clinical practice
- (2019) Massimo Gadina et al. RHEUMATOLOGY
- Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis
- (2019) G. Yosipovitch et al. BRITISH JOURNAL OF DERMATOLOGY
- Pruritus in allergy and immunology
- (2019) Ting-Lin B. Yang et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Characterising Treatment‐related Patient Needs in Atopic Eczema: Insights for Personalised Goal Orientation
- (2019) M. Augustin et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Epidemiology of atopic dermatitis in adults: Results from an international survey
- (2018) S. Barbarot et al. ALLERGY
- Patient-burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study
- (2018) J.I. Silverberg et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t
- (2018) M. de Bruin-Weller et al. BRITISH JOURNAL OF DERMATOLOGY
- Atopic dermatitis
- (2018) Stephan Weidinger et al. Nature Reviews Disease Primers
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
- (2017) Andrew Blauvelt et al. LANCET
- Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
- (2016) Diamant Thaçi et al. LANCET
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
- (2016) Eric L. Simpson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data
- (2015) M.K.A. Basra et al. DERMATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started